SEC Tracker
Get the app

Alkermes ALKS

The Board appointed Mr. Jackson to serve as the Company’s CEO, effective August 1, 2026.

Form
8-K/A
Filed
Importance
Routine
  • Reports an executive or board change (5.02)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Alkermes files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Halozyme Therapeutics HALO public float $4.5B, Jun 30, 2025
  2. Axsome Therapeutics AXSM public float $4.4B, Jun 30, 2025
  3. Lantheus Holdings LNTH public float $4.3B, Jun 30, 2025
  4. Adma Biologics ADMA public float $4.2B, Jun 30, 2025
  5. Ionis Pharmaceuticals IONS public float $5.3B, Jun 30, 2025